In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections

Isnard, Christophe; Dhalluin, Anne; Malandain, D.; Bruey, Quentin; Auzou, Michel; Michon, J.; Giard, Jean‐Christophe; Guérin, François; Cattoir, Vincent

doi:10.1016/j.jgar.2018.01.022

Cited by 13 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All are susceptible in vitro to ceftobiprole with MIC 50/90 of 0.5/1 and one strain of CoNS with a MIC of 4 mg/L. These results are like those obtained by Isnard et al [7] in a study performed on 100 S. aureus strains and 100 CoNS strains cultured from PJIs: all but 2 S. aureus strains (with MIC of 4 mg/L) had MIC lower than 2 mg/L. In another series of 33 strains of S. epidermidis, including one-third multiresistant strains, Hellmark et al [8] found MIC 50 and MIC 90 values of 0.5 and 1.5 mg/L respectively.…”

Section: Discussionsupporting

confidence: 88%

“…In our study, 53.1% of CoNS and 6.6% of S. aureus were methicillin-resistant strains and all were susceptible to ceftobiprole. In the literature, Rouse et al studied the activity of ceftobiprole against MRSA (31 isolates) and CoNS (65 isolates) from bone and joint infections: all strains had MIC ≤ 2 mg/L (except for one CoNS with In addition, the bactericidal activity of ceftobiprole against Staphylococci has been proved in several studies: Isnard et al [7] showed a rapid killing effect, with a significant and sustained decrease of the inoculum after a 24 h incubation period at concentration of 4 * MIC while a phenomenon of re-growth was observed with vancomycin. Rouse et al demonstrated it against 31 methicillin-resistant S. aureus and 65 CoNS isolated from bone and joint infections (all strains had MIC and MBC values ≤ 2 µg/mL, except for one CoNS with MIC and MBC values of 4 and 8 µg/mL) while vancomycin lacked bactericidal activity against 2 MRSA [9].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections

Duployez¹,

Wallet²,

Migaud³

et al. 2020

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

Background: This study aimed to evaluate in vitro susceptibility to ceftobiprole of clinical strains identified from prosthetic joint infections (PJIs) compared to that of the associations currently recommended for post-operative empirical antibiotic therapy (PEAT) (vancomycin with either cefepime, third-generation cephalosporin or piperacillin-tazobactam). Methods: We performed a 1-year retrospective study on all the surgical procedures performed in our hospital for PJI. Susceptibility profiles of all the strains cultured from surgical samples were reviewed to compare ceftobiprole to current used associations. Results: During the study period (from January 2018 to December 2018), we identified 106 patients managed for PJI and a total of 216 surgical interventions. One hundred-fifty strains were identified from intraoperative samples, excluding redundant strains. Staphylococcus spp. represented 52.7% of all strains and Enterobacteriales 13.3%. Twentythree patients had polymicrobial infection (22%). Among 149 surgical procedures with positive culture results, ceftobiprole covered the bacterial strains in 138 (92.6%) cases. In comparison, this percentage was 94.6% for vancomycin plus cefepime (p = 0.64), 92.6% for vancomycin plus a third-generation cephalosporin in 138 cases (p = 1) and 94.6% for vancomycin plus piperacillin-tazobactam) (p = 0.64). Conclusion: Based on antimicrobial susceptibility testing, our results suggest that ceftobiprole could be an interesting option for PEAT in PJIs, allowing the use of a single agent.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections

Duployez¹,

Wallet²,

Migaud³

et al. 2020

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

show abstract

“…Several concentrations of the antibiotic were prepared as follows: 128, 32, 8, 2, 0.5, and 0.2 µg/mL (for Staphylococcus aureus ATCC 6538), and 64, 16, 4, 1, 0.25, and 0.1 µg/mL (for S. aureus ATCC 25923, Bacillus subtilis ATCC 6633, Micrococcus luteus ATCC 10240, S. aureus ATCC 43300, and Bacillus cereus ATCC 10876), and the solutions were spotted on the TLC plates in the following volumes: 20, 10, 5, 2.5, 1.25, and 0.675 µL, respectively. The test concentrations of this antibiotic were selected on the basis of previous studies, where this compound was studied in the microdilution tests, [24,25], and on the basis of the values of peak areas of active components of the extracts for the calibration curves to stay within a similar range.…”

Section: Methodsmentioning

confidence: 99%

Antimicrobial Potential of Single Metabolites of Curcuma longa Assessed in the Total Extract by Thin-Layer Chromatography-Based Bioautography and Image Analysis

Czernicka

Grzegorczyk

Marzec

et al. 2019

IJMS

View full text Add to dashboard Cite

Curcuma longa from Zingiberaceae belongs to the major spices consumed around the world, known from its cholagogue, anti-inflammatory, and antimicrobial properties. Lack of data on the activity of single components of turmeric extract encouraged the authors to apply TLC (thin-layer chromatography) based bioautography studies to reveal its antimicrobial constituents and construct a universal platform for the bioactivity assessment of crude extracts, with help of a freeware ImageJ software. This optimized chromatographic bioassay performed on diethyl ether and methanol extracts of Curcuma longa was successfully applied on the total extract and revealed the antimicrobial potential of single components against a variety of Gram-positive strains, with no need for their isolation from the mixture. The obtained results were further confronted with a classic microdilution antimicrobial assay on the isolates, purified from the crude extracts by centrifugal partition chromatography in the following solvent system: heptane-chloroform-methanol-water (5:6:3:2) (v/v/v/v).

show abstract

“…infections of devices). Indeed, ceftobiprole showed remarkable activity against staphylococcal isolates from foreign body-associated infections and prosthetic joint infections [23,24].…”

Section: Article Highlightsmentioning

confidence: 99%

Ceftobiprole: drug evaluation and place in therapy

Giacobbe

Rosa

Bono

et al. 2019

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: Ceftobiprole is a fifth-generation cephalosporin with a broad spectrum of antimicrobial activity, including also methicillin-resistant Staphylococcus aureus (MRSA). Ceftobiprole is approved for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia, in several European and non-European countries. Areas covered: In this narrative review, we discuss the current place in therapy of ceftobiprole, both within and outside approved indications. An inductive MEDLINE/PubMed search of the available literature was conducted. Expert opinion: There are three main reasons which render ceftobiprole an attractive option for the empirical and targeted treatment of CAP and HAP: (i) its broad spectrum of activity; (ii) its activity against MRSA; (iii) its good safety profile. For these indications, ceftobiprole should be employed thoughtfully, in those scenarios in which its intrinsic advantages could be maximized. The use of ceftobiprole outside approved indications could be justified in specific scenarios, such as when other approved alternatives are ineffective, when the risk of toxicity due to other agents is unacceptable, and for salvage therapy. In the near future, ongoing phase 3 studies and further observational experiences could both enlarge the current panel of approved indications and enrich our knowledge on the use of ceftobiprole for off-label indications. ARTICLE HISTORY

show abstract

In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections

Cited by 13 publications

References 19 publications

Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections

Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections

Antimicrobial Potential of Single Metabolites of Curcuma longa Assessed in the Total Extract by Thin-Layer Chromatography-Based Bioautography and Image Analysis

Ceftobiprole: drug evaluation and place in therapy

Contact Info

Product

Resources

About